In this free webinar, learn about the current landscape of antibody-drug conjugates and radionuclide conjugates. Attendees will gain insights into regulatory constructs, submission readiness, dose structuring and optimization. The featured speakers will discuss Project Optimus implications, first-in-human design considerations and constructs, as well as clinical pharmacology considerations. Attendees will gain operational insights for clinical trials of antibody-drug conjugates and radionuclide conjugates.
TORONTO, Aug. 14, 2024 /PRNewswire-PRWeb/ -- This informative webinar will provide a comprehensive examination of the development lifecycle of radionuclide conjugates and antibody-drug conjugates from initial research to clinical application.
With innovation, investment and regulatory support accelerating radionuclide conjugate and antibody-drug conjugate research, understanding the drug development landscape is crucial to recognizing opportunities for development, anticipating challenges and strategizing effectively. Knowledge of regulatory constructs and efficient clinical development — including study design, dose and regimen selection and optimization — is essential to navigate the complex approval process and maximize therapeutic efficacy while minimizing side effects.
In this webinar, key considerations for dose selection optimization will be discussed, with a focus on how Project Optimus influences these processes to enhance dose-finding strategies as well as the design constructs of first-in-human trials. Clinical pharmacology considerations will be explored, underscoring the unique pharmacokinetic and pharmacodynamic profiles of radionuclide conjugates and antibody-drug conjugates that differentiate them from traditional small molecules.
Finally, the speakers will share operational considerations for clinical trials, including site selection and meeting patient needs, both of which are critical to the successful execution and progression of trials involving these advanced therapeutic agents. This structured approach aims to provide a clear roadmap for the integrated development and clinical implementation of radionuclide conjugates and antibody-drug conjugates, ensuring their successful transition from research to patient care.
Register for this webinar today to gain a deeper understanding of the transformative potential of antibody-drug conjugates and radionuclide conjugates and learn why they are pivotal in the advancement of precision medicine and significantly improving patient outcomes in oncology.
Join experts from Allucent, Alex MacDonald, PhD, Vice President, Model-Informed Drug Development; Sugato De, MS, Vice President, Regulatory Strategy, Head of Medical Technology, Angela Brady, MHL, Senior Vice President, Global Head of Project Leadership and Client Relations and Dr. Brian Barnett, MD, Executive Medical Director, Oncology for the live webinar on Thursday, September 5, 2024, at 11am EDT (4pm BST/UK).
For more information, or to register for this event, visit Advancing Precision Oncology: Radionuclide Conjugate and Antibody-Drug Conjugate (ADC) Development Strategies.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected], https://xtalks.com
SOURCE Xtalks
Share this article